| Literature DB >> 23008818 |
Litha Thomas1, Vidya Viswanad.
Abstract
The main aim of the study was to develop and statistically optimize the proniosomal gel for enhanced transdermal delivery using 3(2) factorial designs to investigate the influence of both non-ionic surfactant and cholesterol to maximize the entrapment efficiency and flux. The concentration of non-ionic surfactant and cholesterol were taken as independent variables, while entrapment efficiency and flux were taken as dependent variables. The study showed that the entrapment efficiency depends on both cholesterol and surfactant, whereas permeation flux depends only on the surfactant. Proniosomal gel showed a significantly enhanced drug permeation through the skin, with an enhancement ratio 3.81±1.85 when compared to the drug solution. Comparative evaluation of permeation studies and the in vitro release study of optimized proniosomal gel (F5) with that of marketed gel and carbopol gel showed that the penetration of the optimized formulation was enhanced 1.75 times in comparison with that of the marketed formulation, and the release was in a controlled manner. Similarly, the anticandidial activity showed a significantly higher activity (p<0.05) than the marketed and carbopol gel. This may be due to the enhanced penetration of noisome-containing drug through the fungal cell wall, inhibiting the ergo sterol synthesis, thereby causing the fungal cell death due to the presence of penetration enhancer. The stability study at two different temperatures (30 ± 2°C and 4 ± 2°C) confirmed that the formulations were stable even at the end of 45 days. Hence, proniosomal gel is an efficient carrier for the delivery of clotrimazole, thereby prolonging the action.Entities:
Keywords: Cholesterol; Clotrimazole; Entrapment efficiency; Factorial design; Flux; Surfactant
Year: 2012 PMID: 23008818 PMCID: PMC3447614 DOI: 10.3797/scipharm.1201-03
Source DB: PubMed Journal: Sci Pharm ISSN: 0036-8709
Representing the Composition of Formulation
| INGREDIENTS | FORMULATION CODE | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | |
| Surfactant (mg) | 90 | 90 | 90 | 180 | 180 | 180 | 270 | 270 | 270 |
| Cholesterol (mg) | 15 | 30 | 45 | 15 | 30 | 45 | 15 | 30 | 45 |
| Lecithin (mg) | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 |
| Ethanol (ml) | 0.135 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Water (ml) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Drug (%) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Correlation of actual and coded factors
| FACTOR | CODED | ACTUAL VALUE (mg) | |
|---|---|---|---|
| SURFACTANT | CHOLESTEROL | ||
| LOW | −1 | 90 | 15 |
| MEDIUM | 0 | 180 | 30 |
| HIGH | +1 | 270 | 45 |
Observed Response in 32 Factorial Design for Clotrimazole-loaded Proniosomal Gel
| FORMULATION CODE | VARIABLES | |||
|---|---|---|---|---|
|
| ||||
| INDEPENDENT | DEPENDENT | |||
|
|
| |||
| A | B | Y1 | Y2 | |
| F1 | −1 | −1 | 60.6023 ± 0.673865 | 5.244 ± 1.310 |
| F2 | −1 | 0 | 63.8263 ± 2.79596 | 4.9254 ± 0.95 |
| F3 | −1 | 1 | 52.2267 ± 1.555 | 4.319 ± 1.059 |
| F4 | 0 | −1 | 91.7233 ± 1.54043 | 8.60 ± 2.087 |
| F5 | 0 | 0 | 95.4053 ± 1.40069 | 9.453 ± 2.022 |
| F6 | 0 | 1 | 77.5213 ± 2.00448 | 7.241 ± 0.317 |
| F7 | 1 | −1 | 82.3463 ± 1.55203 | 9.163 ± 1.045 |
| F8 | 1 | 0 | 86.8763 ± 0.553715 | 10.770 ± 1.245 |
| F9 | 1 | 1 | 65.7707 ± 2.26477 | 5.775 ± 0.438 |
The values are expressed as Mean ± SD; n = 3,
Optimized Formulation.
Representing the Flux and Enhancement Ratio of the Proniosomal Gel
| FORMULATION CODE | PERMEABILITY FLUX | ENNHANCEMENT RATIO |
|---|---|---|
| F1 | 5.244 ± 1.310 | 1.76 |
| F2 | 4.9254 ± 0.95 | 1.65 |
| F3 | 4.319 ± 1.059 | 1.45 |
| F4 | 8.60 ± 2.087 | 2.89 |
| F5 | 9.453 ± 2.022 | 3.27 |
| F6 | 7.241 ± 0.317 | 2.43 |
| F7 | 9.163 ± 1.045 | 3.07 |
| F8 | 10.770 ± 1.245 | 3.61 |
| F9 | 5.775 ± 0.438 | 1.93 |
| Drug Solution | 2.98±0.52 |
ANOVA Analysis of Entrapment Efficiency
| Source | Sum of Squares | Df | Mean Square | F-Ratio | P-Value |
|---|---|---|---|---|---|
| A:Surfactant | 567.22 | 1 | 567.22 | 155.64 | 0.0011 |
| B:Cholesterol | 255.496 | 1 | 255.496 | 70.10 | 0.0036 |
| AA | 768.989 | 1 | 768.989 | 211.00 | 0.0007 |
| AB | 16.81 | 1 | 16.81 | 4.61 | 0.1210 |
| BB | 213.729 | 1 | 213.729 | 58.64 | 0.0046 |
| Total error | 10.9335 | 3 | 3.64451 | ||
| Total (corr.) | 1833.18 | 8 |
Significant values.
ANOVA Analysis of Permeation Flux
| Source | Sum of Squares | Df | Mean Square | F-Ratio | P-Value |
|---|---|---|---|---|---|
| A:Surfactant | 20.9799 | 1 | 20.9799 | 17.73 | 0.0245 |
| B:Cholesterol | 5.36193 | 1 | 5.36193 | 4.53 | 0.1232 |
| AA | 5.99919 | 1 | 5.99919 | 5.07 | 0.1098 |
| AB | 1.51659 | 1 | 1.51659 | 1.28 | 0.3399 |
| BB | 5.50545 | 1 | 5.50545 | 4.65 | 0.1199 |
| Total error | 3.55046 | 3 | 1.18349 | ||
| Total (corr.) | 42.9135 | 8 |
Significant values.
Desirability correlation of formulations
| FORMULATION CODE | PREDICTED DESIRABILITY | OBSERVED DESIRABLITY |
|---|---|---|
| F1 | 0.00720162 | 0.00436896 |
| F2 | 0.0135459 | 0.027096 |
| F3 | 0.0000465304 | 0.0 |
| F4 | 0.632078 | 0.626386 |
| F5 | 0.865704 | 0.855237 |
| F6 | 0.165684 | 0.170966 |
| F7 | 0.320917 | 0.365422 |
| F8 | 0.524163 | 0.426302 |
| F9 | 0.0260801 | 0.0329907 |
significant formulation.
Evaluation in vitro Antifungal Activity by Zone of Inhibition
| Zone of inhibition of Test samples(mm) | ||||
|---|---|---|---|---|
|
| ||||
| Microorganism | Concentr. (μg/ml) | Marketed (K1) | Optimized Formulation (K3) | Carbopol gel (K4) |
| 1000 | 18.4 ± 0.89 | 25.2 ± 1.10 | 21.4 ± 1.14 | |
| 500 | 12.2 ± 0.84 | 22 ± 1.22 | 17 ± 1 | |
The values are expressed as Mean ± SD; n = 5.
Stability Study of Optimized formulation
| TEMPERATURE | PERCENTAGE DRUG RETAINED (%) | |||
|---|---|---|---|---|
|
| ||||
| Refrigerator (4 ± 2°C) | 99.72 | 99.30 | 99.17 | 98.69 |
| Room Temperature (30 ± 2°C) | 99.43 | 99.17 | 98.99 | 98.39 |